1. Home
  2. NVST vs DNTH Comparison

NVST vs DNTH Comparison

Compare NVST & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Envista Holdings Corporation

NVST

Envista Holdings Corporation

HOLD

Current Price

$28.30

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$107.86

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVST
DNTH
Founded
2018
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.5B
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
NVST
DNTH
Price
$28.30
$107.86
Analyst Decision
Buy
Strong Buy
Analyst Count
13
13
Target Price
$26.46
$121.00
AVG Volume (30 Days)
3.0M
874.9K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
104.31
N/A
EPS
0.56
N/A
Revenue
$2,566,500,000.00
$2,036,000.00
Revenue This Year
$6.67
N/A
Revenue Next Year
$3.55
$29.48
P/E Ratio
$48.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.77
$18.08
52 Week High
$30.42
$114.55

Technical Indicators

Market Signals
Indicator
NVST
DNTH
Relative Strength Index (RSI) 53.77 59.17
Support Level $25.49 $100.00
Resistance Level $28.43 N/A
Average True Range (ATR) 0.83 5.74
MACD 0.05 0.23
Stochastic Oscillator 52.51 68.18

Price Performance

Historical Comparison
NVST
DNTH

About NVST Envista Holdings Corporation

Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: